Your browser doesn't support javascript.
loading
EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres.
Chiesa, Carlo; Sjogreen-Gleisner, Katarina; Walrand, Stephan; Strigari, Lidia; Flux, Glenn; Gear, Jonathan; Stokke, Caroline; Gabina, Pablo Minguez; Bernhardt, Peter; Konijnenberg, Mark.
Afiliación
  • Chiesa C; Nuclear Medicine Unit, Foundation IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Sjogreen-Gleisner K; Department of Medical Radiation Physics, Lund University, Lund, Sweden.
  • Walrand S; Nuclear Medicine, Molecular Imaging, Radiotherapy and Oncology Unit (MIRO), IECR, Université Catholique de Louvain, Brussels, Belgium.
  • Strigari L; Medical Physics Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Flux G; Joint Department of Physics, Royal Marsden Hospital & Institute of Cancer Research, Sutton, UK.
  • Gear J; Joint Department of Physics, Royal Marsden Hospital & Institute of Cancer Research, Sutton, UK.
  • Stokke C; Department of Diagnostic Physics, Oslo University Hospital, Oslo, Norway.
  • Gabina PM; Department of Medical Physics and Radiation Protection, Gurutzeta/Cruces University Hospital, Barakaldo, Spain.
  • Bernhardt P; Department of Radiation Physics, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Konijnenberg M; Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
EJNMMI Phys ; 8(1): 77, 2021 Nov 12.
Article en En | MEDLINE | ID: mdl-34767102
The aim of this standard operational procedure is to standardize the methodology employed for the evaluation of pre- and post-treatment absorbed dose calculations in 90Y microsphere liver radioembolization. Basic assumptions include the permanent trapping of microspheres, the local energy deposition method for voxel dosimetry, and the patient-relative calibration method for activity quantification.The identity of 99mTc albumin macro-aggregates (MAA) and 90Y microsphere biodistribution is also assumed. The large observed discrepancies in some patients between 99mTc-MAA predictions and actual 90Y microsphere distributions for lesions is discussed. Absorbed dose predictions to whole non-tumoural liver are considered more reliable and the basic predictors of toxicity. Treatment planning based on mean absorbed dose delivered to the whole non-tumoural liver is advised, except in super-selective treatments.Given the potential mismatch between MAA simulation and actual therapy, absorbed doses should be calculated both pre- and post-therapy. Distinct evaluation between target tumours and non-tumoural tissue, including lungs in cases of lung shunt, are vital for proper optimization of therapy. Dosimetry should be performed first according to a mean absorbed dose approach, with an optional, but important, voxel level evaluation. Fully corrected 99mTc-MAA Single Photon Emission Computed Tomography (SPECT)/computed tomography (CT) and 90Y TOF PET/CT are regarded as optimal acquisition methodologies, but, for institutes where SPECT/CT is not available, non-attenuation corrected 99mTc-MAA SPECT may be used. This offers better planning quality than non dosimetric methods such as Body Surface Area (BSA) or mono-compartmental dosimetry. Quantitative 90Y bremsstrahlung SPECT can be used if dedicated correction methods are available.The proposed methodology is feasible with standard camera software and a spreadsheet. Available commercial or free software can help facilitate the process and improve calculation time.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: EJNMMI Phys Año: 2021 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: EJNMMI Phys Año: 2021 Tipo del documento: Article País de afiliación: Italia